The Lira-1 trial was a landmark study assessing the safety and efficacy of liraglutide (1.8 mg) added to insulin therapy in adults with T1DM and BMI > 25 kg/m2 [19]. The gene discussed is INS; the disease is type 1 diabetes mellitus.